Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00067)
Name
Betrixaban
Synonyms    Click to Show/Hide the Synonyms of This API
Betrixaban; 330942-05-7; PRT054021; Bevyxxa; N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide; UNII-74RWP7W0J9; PRT 054021; N-(5-Chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide; PRT-054021; 74RWP7W0J9; CHEMBL512351; 330942-05-7 (free base); N-(5-Chloropyridin-2-yl)-2-((4-(N,N-dimethylcarbamimidoyl)benzoyl)amino)-5- methoxybenzamide; Betrixaban [USAN:INN]; betrixaban/; N-(5-chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide; Bevyxxa (TN); Betrixaban (USAN); SCHEMBL158591; GTPL9602; QCR-99; DTXSID10954727; EX-A358; CHEBI:140421; BCP01903; ABP000384; BDBM50249298; MFCD16038040; ZINC30691754; AKOS005146070; BCP9000395; CCG-269250; DB12364; SB16951; VA11998; compound 11 [PMID: 19297154]; NCGC00371122-02; NCGC00371122-04; AC-30214; AS-56192; HY-10268; AB0027977; DB-068750; FT-0663094; D08873; 942B057; Q4898219; Benzamide, N-(5-chloro-2-pyridinyl)-2-((4-((dimethylamino)iminomethyl)benzoyl)amino)-5-methoxy-; N-(5-Chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzene-1-carboximidic acid
Clinical Status
Approved
Disease Indication Venous thromboembolism ICD-11: BD72 [1]
PubChem CID
10275777
Formula
C23H22ClN5O3
Canonical SMILES
CN(C)C(=N)C1=CC=C(C=C1)C(=O)NC2=C(C=C(C=C2)OC)C(=O)NC3=NC=C(C=C3)Cl
InChI
1S/C23H22ClN5O3/c1-29(2)21(25)14-4-6-15(7-5-14)22(30)27-19-10-9-17(32-3)12-18(19)23(31)28-20-11-8-16(24)13-26-20/h4-13,25H,1-3H3,(H,27,30)(H,26,28,31)
InChIKey
XHOLNRLADUSQLD-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=10275777"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 451.9 Topological Polar Surface Area 107
XlogP 3.6 Complexity 668
Heavy Atom Count 32 Rotatable Bond Count 7
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
Full List of Drug Formulations (DFMs) Containing This API
          Betrixaban 80 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Dextrose monohydrate; Fd&c blue no. 1; Magnesium stearate; Ferric oxide yellow; Ferrosoferric oxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified
                   Dosage Form Oral Capsule
                   Company Portola Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
          Betrixaban 40 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Dextrose monohydrate; Fd&c blue no. 1; Magnesium stearate; Ferrosoferric oxide; Titanium dioxide; Croscarmellose sodium; Gelatin, unspecified
                   Dosage Form Oral Capsule
                   Company Portola Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 1 DIG Info Solute carrier SLCO2B1 (Ki = 13 uM) [2]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [3]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [3]
References
1 FDA label for approved betrixaban from the official website of the U.S. Food and Drug Administration.
2 Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):16009-16018.
3 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.